Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Nov 3, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Phase III Trial Demonstrates Shorter, Hypofractionated RT Can Deliver Similar Results Compared to Conventional RT

 

Hypofractionated radiation therapy, which is delivered in larger doses over a shorter time period than conventional RT, can result in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research presented at the American Society for Radiation Oncology’s annual meeting.

A phase III study, RTOG 0415, was conducted from April 2006 to December 2009 across the U.S. and Canada and compared the five-year disease-free survival rate in men with low-risk prostate cancer.

Baseline characteristics were similar between the two treatment arms, including the patients’ median age of 65 and pretreatment prostate specific antigen scores, with median PSA equal to 5.4 ng/mL. The study also looked at overall survival rates and patients’ biochemical recurrence.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter